glp-1 receptor agonists muscle mass preservation 2025 Glucagon-like peptide-1 and effects Emerging Role of Myostatin Inhibitors
Description
The GLP-1 receptor agonist market is growing rapidly, supported by rising obesity and diabetes prevalence, strong clinical outcomes, and increasing patient awareness
Diabetes care, 39 ,
Questions around long-term sustainability and real-world access
D.Snchez-PayJ.De MadariaE.Robles-DazG.Prez-MateoM
This timeline indicates that the first cases may reach juries by late 2026 or early 2027, though the pace could accelerate if settlement negotiations gain momentum after key pretrial rulings
Good platforms present these terms in plain language
